



HAL
open science

The TGF- β /Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system

Eliza Wiercinska, Hildegonda P. H. Naber, Evangelia Pardali, Gabri Pluijm, Hans Dam, Peter Dijke

► To cite this version:

Eliza Wiercinska, Hildegonda P. H. Naber, Evangelia Pardali, Gabri Pluijm, Hans Dam, et al.. The TGF- β /Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. *Breast Cancer Research and Treatment*, 2010, 128 (3), pp.657-666. 10.1007/s10549-010-1147-x . hal-00615376

HAL Id: hal-00615376

<https://hal.science/hal-00615376>

Submitted on 19 Aug 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

The TGF- β /Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system.

Eliza Wiercinska* · Hildegonda P. H. Naber* · Evangelia Pardali · Gabri van der Pluijm · Hans van Dam · Peter ten Dijke

*These authors contributed equally

E. Wiercinska · H. Naber · E. Pardali · H. van Dam · P. ten Dijke

Department of Molecular Cell Biology and Centre for Biomedical Genetics, Leiden University Medical Center, P.O. box 9600, 2300 RC, Leiden, The Netherlands

G. van der Pluijm

Dept. of Urology and Endocrinology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands

P. ten Dijke

Ludwig Institute for Cancer Research and Uppsala University, Box 595, 75124, Uppsala, Sweden.

Corresponding author: P. ten Dijke, Building 2, Room R-02-022, Leiden University Medical Center, Postzone S-1-P, PO Box 9600, 2300 RC Leiden, The Netherlands.

Email: p.ten_dijke@lumc.nl; Tel: +31-71-5269271. Fax: +31-71-5268270

Abstract

Transforming growth factor- β (TGF- β) has opposing roles in breast cancer progression by acting as a tumor suppressor in the initial phase, but stimulating invasion and metastasis at later stages. In contrast to the mechanisms by which TGF- β induces growth arrest, the pathways that mediate tumor invasion are not well understood. Here, we describe a TGF- β -dependent invasion assay system consisting of spheroids of MCF10A1 normal breast epithelial cells (M1) and RAS-transformed (pre-)malignant derivatives (M2 and M4) embedded in collagen gels. Both basal and TGF- β -induced invasion of these cell lines was found to correlate with their tumorigenic potential; M4 showing the most aggressive behavior and M1 showing the least. Basal invasion was strongly inhibited by the TGF- β receptor kinase inhibitor SB-431542, indicating the involvement of autocrine TGF- β or TGF- β -like activity. TGF- β -induced invasion in premalignant M2 and highly malignant M4 cells was also inhibited upon specific knockdown of Smad3 or Smad4. Interestingly, both a broad spectrum matrix metalloproteinase (MMP) inhibitor and a selective MMP2 and MMP9 inhibitor mitigated TGF- β -induced invasion of M4 cells, while leaving basal invasion intact. In line with this, TGF- β was found to strongly induce MMP2 and MMP9 expression in a Smad3- and Smad4-dependent manner. This collagen-embedded spheroid system therefore offers a valuable screening model for TGF- β /Smad- and MMP2- and MMP9-dependent breast cancer invasion.

Keywords invasion · matrix metalloproteinase · spheroids · MCF10A · Smad · TGF- β

Introduction

Breast cancer is one of the leading causes of death in women. Morbidity and mortality are predominantly caused by metastasis, but not by the primary tumor. A critical event in the metastatic cascade is tumor cell invasion. However, the mechanisms by which primary tumor cells acquire an invasive phenotype are not well known. One of the inducers of invasion is transforming growth factor- β (TGF- β). TGF- β is thought to play a dual role in cancer progression [1,2]. It can act as a tumor suppressor in the early stages, but promote cancer progression in later stages of the disease. Moreover, TGF- β is frequently overexpressed in breast cancer and its expression correlates with poor prognosis and metastasis [3–6].

TGF- β elicits its cellular responses via TGF- β type II (T β RII) and type I (T β RI) receptors. Upon TGF- β -induced heteromeric complex formation, T β RII phosphorylates T β RI. The activated T β RI initiates its intracellular canonical signaling pathway by phosphorylating receptor Smads (R-Smads), i.e. Smad2 and Smad3. These activated R-Smads form heteromeric complexes with Smad4, which accumulate in the nucleus and regulate the transcription of target genes [7,8]. Tumor suppressor activities of TGF- β /Smad signaling include amongst others repression of c-myc [9] and induction of cyclin-dependent kinase inhibitors [10,11].

During cancer progression accumulation of genetic mutations as well as epigenetic changes can render cells insensitive to the cytostatic effects of TGF- β , and components of the TGF- β pathway are frequently inactivated in a subset of cancer specimens [12]. However, breast and other cancers often only carry defects in downstream cytostatic TGF- β targets, show normal TGF- β signaling from receptors

to Smads, and retain or gain other TGF- β responsive properties [13–16]. One of the TGF- β -induced processes contributing to tumor migration and invasion is epithelial-to-mesenchymal transition (EMT). Both Smad and non-Smad signaling pathways have been implicated in TGF- β -induced EMT of breast cancer cells [17–19]. In addition, matrix metalloproteinases (MMPs) appear to play a critical role in TGF- β -induced migration and invasion [20–22].

To study the role of TGF- β in different stages of breast cancer, we made use of the MCF10A cell system. This system consists of immortalized MCF10A1 (M1) normal breast epithelial cells (derived from human fibrocystic mammary tissue [23]), the H-RAS transformed M1-derivative MCF10AneoT (M2), which produces premalignant lesions in mice, and the M2-derivative MCF10CA1a (M4), which was established from M2 xenografts and forms high grade carcinomas with the ability to metastasize to the lung [24,25]. Since RAS and TGF- β have been reported to collaborate in promoting malignant progression of breast cancer [26,27], this MCF10A series offers the possibility to study the responses of cells with different grades of malignancy that are not biased by a different genetic background.

For the analysis of TGF- β -induced invasion we generated homotypic MCF10A spheroid cell cultures embedded in a 3D collagen matrix *in vitro*. Such models closely resemble human tumors *in vivo* by establishing a gradient of oxygen and nutrients, resulting in active and invasive cells on the outside and quiescent or even necrotic cells in the inside of the spheroid [28,29]. Spheroid based assays have also been shown to better predict drug resistance than monolayer cultures [30,31]. This MCF10 3D model system allowed us to investigate the impact of TGF- β signaling on the invasive properties of breast cells in different stages of malignancy.

Our results show that both Smads and MMP2 and in particular MMP9 are critical for TGF- β -induced invasion of the malignant breast cancer cells.

Materials and methods

Cell culture

MCF10A series of cell lines, i.e. MCF10A (M1), transformed MCF10AneoT (M2) and its derivative MCF10CA1a (M4) were obtained from Dr. Fred Miller (Barbara Ann Karmanos Cancer Institute, Detroit, USA). All MCF10A cell lines were maintained in DMEM/F12 (Gibco) supplemented with 5% horse serum (Gibco), 20ng/ml epidermal growth factor (EGF) (Upstate), 100ng/ml cholera toxin (Calbiochem), 0.5 μ g/ml hydrocortisone (Sigma), 10 μ g/ml insulin (Sigma), 100U/ml penicillin and 50 μ g/ml streptomycin (Gibco). All cell lines were grown in a humidified incubator at 37°C and 5% CO₂.

3D spheroid invasion assays

Semi-confluent MFC10A cells were trypsinized, counted and re-suspended in medium containing 2.4mg/ml methylcellulose (Sigma) at the concentration of 10⁴ cells/ml. 100 μ l of suspension was added into each well of U-bottom 96-well-plate allowing the formation of one spheroid per well. All spheroids consisted of 10³ cells. Two days after plating spheroids were harvested and embedded into collagen. Flat-bottom 96-well-plate was coated with neutralized bovine collagen-I (PureCol, Advanced BioMatrix) according to manufacturer's protocol. Single spheroids were

embedded in a 1:1 mix of neutralized collagen and medium supplemented with 12mg/ml of methylcellulose. TGF- β 3 (generous gift of Dr. K. Iwata, OSI Pharmaceuticals, Inc, New York, USA) and/or SB-431542 (Sigma) were directly added to the embedding solution. GM6001 and MMP2/9-inhibitor II (Calbiochem) were added in medium on top of the collagen. Invasion was monitored during the next two days and quantified by measuring the area occupied by cells using ImageJ software. Pictures were taken at day 0 and day 2 after embedding.

Lentiviral transduction

Lentiviral constructs expressing short hairpin RNAs targeting Smad4 (sh-Smad4) or a non-targeting control were obtained from the Sigma Mission shRNA library. The targeting sequence for Smad4 was 5'-GTA^{CTTC}A^{TACCATG}CCGATT-3'. The non-targeting sequence was 5'-AGA^{ACGTCAACACCA}AGTGCA-3'. Smad3 knockdown was performed using miR-Smad3 lentivirus using BLOCK-iT Pol II micro RNA interference technology (Invitrogen) as described previously [32]. Cells were infected at multiplicity of infection (MOI) 2, selected with appropriate antibiotics (sh-Smad4 and the non-targeting control cells with puromycin; miR-Smad3 and miR-control cells with blasticidin), and used for experiments one week later.

Gelatin zymography

Conditioned medium was harvested from cells after 48 hr of stimulation and resuspended in 4x Laemli buffer (250mM Tris-HCl pH6.8, 8% SDS, 40% glycerol,

0.004% bromophenol blue). Samples were ran on a 10% acrylamide gel containing 0.8mg/ml gelatin, washed with 2.5% Triton and incubated at 37°C with Brij solution (50mM Tris-HCl pH7.4, 0.05% Brij-35, 10mM CaCl₂) overnight. Gels were stained with Coomassie Brilliant Blue (25% methanol, 15% acetic acid, 0.1% Coomassie Brilliant Blue R).

Statistical analysis

For statistical comparison of two groups, a two-tailed Student's *t*-test was used where applicable. Statistical analysis of three or more groups was done by one-way ANOVA followed by Bonferroni's multiple comparison test. *P*<0.05 was considered as statistically significant.

Other assays

Assays for cell proliferation, transcriptional reporter activity, Western blot analysis, RNA isolation, cDNA synthesis and quantitative PCR are found in supplementary methods

Results

Establishment of a spheroid cell culture model to study TGF- β -induced invasion of breast cancer cells

To analyze the role of TGF- β -signaling in 3D cultures, spheroids of MCF10A1 (M1) normal breast epithelial cells, H-RAS transformed MCF10AneoT

(M2) cells, or M2-derived MCF10CA1a (M4) cells were embedded into collagen matrix and stimulated with TGF- β (Fig. 1a). M1 cells showed only weak invasion without stimulation, but invaded significantly better upon TGF- β stimulation. In contrast, the RAS-transformed M1-derivative M2 invaded already efficiently without any stimulus, which was further increased 4-5 fold upon TGF- β addition. M4 cells showed the strongest invasion, both with and without TGF- β addition (Fig. 1a, b), in line with their metastatic capacity. Other TGF- β family ligands, such as Activin-A, BMP-6, BMP-7 or BMP-9 failed to induce invasion in any of the cell lines (data not shown). Thus, the invasiveness in our spheroid model *in vitro* correlates with the grade of aggressiveness of the M1, M2 and M4 cells *in vivo* [24,25].

Next, we examined whether the differences in invasion between M1, M2 and M4 cells can be explained by differences in TGF- β responsiveness. All three cell lines were found to express type I, II and III receptors as shown by TGF- β affinity crosslinking assays (Suppl. Fig. 1b), which is in line with a previous study [33]. To investigate if all cells activate TGF- β /Smad transcriptional activity to the same extent, we made use of the CAGA₁₂-luciferase reporter, which contains 12 repeats of the Smad binding element CAGA. All cells showed TGF- β /Smad transcriptional activity in response to TGF- β . However, induction in M2 was markedly lower than in M1 and M4 (Suppl. Fig. 1a). Furthermore, all cells showed Smad2 phosphorylation upon TGF- β stimulation (data not shown). Thus, the differences in receptor binding and transcriptional activity did not correlate with the levels of spheroid invasiveness of the three cell lines.

TGF- β is a potent inhibitor of proliferation of epithelial cells and this inhibitory effect is often lost during cancer progression. To test whether the

differences in basal and TGF- β -induced invasion between M1, M2 and M4 cells is associated with differences in growth rate, we performed proliferation assays. Interestingly, the growth of all three cell lines was slightly inhibited by TGF- β , but no major differences were detected between the cell lines (Fig. 1c).

Taken together, our results demonstrate that the described spheroid invasion assay closely reproduces the differences in the aggressive properties of the three cell lines [24,25,33], whereas the observed differences are not due to differences in proliferative capacity or responsiveness to TGF- β .

SB-431542 inhibits basal and TGF- β -induced invasion

Next, we examined whether the basal and TGF- β -induced invasion in this spheroid model is dependent on the T β RI kinase. For this purpose we used SB-431542, an ATP analogue and selective inhibitor of the kinase activity of T β RI, activin type IB receptor (ActRIB) and activin receptor-like kinase (ALK)7 [34]. As expected, SB-431542 potently inhibited TGF- β -induced invasion of M1, M2 and M4 cells (Fig 2a, b), indicating that TGF- β -induced invasion is T β RI-kinase dependent. Surprisingly, the basal invasion of the spheroids was also strongly inhibited, suggesting autocrine TGF- β signaling, since we found these cells to express all TGF- β isoforms. The basal invasion of M1, M2 and/or M4 cells might also be mediated by ligands other than TGF- β , e.g. ligands that signal via ActRIB and ALK7. However, Activin-A failed to induce invasion (data not shown) and only marginally induced CAGA₁₂-luciferase transcriptional activity, possibly caused by low expression of activin receptors in these cells (Suppl. Fig. 1a).

TGF- β -induced invasion is Smad3/4 dependent

As TGF- β signaling potently induced invasion of the aggressive and metastatic M4 cells, we used these cells to further investigate the role of the TGF- β pathway in metastasis-associated invasion. Recent studies by our group and others have demonstrated that Smad3 and Smad4 are key players in inducing metastasis of MDA-MB231 cells [17,32,35]. To investigate the role of Smad3 and Smad4 in M4, we knocked-down Smad3 and Smad4 through lentiviral vectors. The Smad4 shRNA construct used strongly reduced Smad4 protein, but did not affect the TGF- β -induced phosphorylation of Smad2 and Smad3 (Fig. 3a). The Smad4 knockdown vector also strongly reduced TGF- β /Smad-induced transcription as measured by a CAGA₁₂-luciferase reporter (Fig. 3b). Moreover, M4 spheroids embedded in collagen showed a severe defect in TGF- β -induced invasion upon Smad4 knockdown (Fig. 3c and d), indicating that TGF- β -induced 3D invasion is Smad4-dependent.

Although the knockdown of Smad3 was less efficient than the knockdown of Smad4, it significantly reduced the levels of phospho-Smad3, while leaving TGF- β -induced phosphorylation of Smad2 unaffected (Fig. 3a). Moreover, this level of Smad3-knockdown, like knockdown of Smad4, severely inhibited TGF- β /Smad-induced transcription (Fig. 3b). Knockdown of Smad3 also reduced the levels of TGF- β -induced invasion of M4 cells in collagen (Fig. 3c and d).

To further investigate the role of Smads in TGF- β -induced invasion we performed knockdown experiments in the premalignant cell line M2 (Suppl. Fig. 2a). Also in these cells Smad3 or Smad4 knockdown caused inhibition of TGF- β -induced invasion (Suppl. Fig. 2b and c). Taken together, these results emphasize the importance of the Smad3/4 pathway in TGF- β -induced invasion.

Critical role of MMP2 and 9 in TGF- β -induced invasion

Next, we asked ourselves which downstream target genes are necessary for TGF- β -induced invasion in this model system. MMPs play important roles in tumor cell migration and invasion, both through degradation of components of the extracellular matrix, and by activation of growth factors and cleavage of adhesion molecules [36]. Analysis of TGF- β -induced mRNA expression identified MMP1, MMP2 and MMP9 among the strongest TGF- β -responsive genes in M4 spheroids (Suppl. Fig. 3a and Fig. 4a, b, respectively). Since the spheroid assay is performed in collagen I matrix, MMP1, a known collagen I protease, was expected to be a critical mediator of TGF- β -induced invasion. However, knockdown experiments showed that MMP1 is not necessary for TGF- β -induced invasion in this system (Suppl. Fig. 3b-d). We next examined the involvement of the gelatinases MMP2 and MMP9, as these proteins have been correlated with poor prognosis and lung metastasis in breast cancer [37,38]. TGF- β was found to strongly induce MMP2 and MMP9 mRNA levels both in spheroids (3D) and in monolayer (2D): MMP2 expression was induced approximately 10-fold upon TGF- β stimulation in both 2D and 3D (Fig. 4a and 4b); MMP9 approximately 100-fold and 40-fold in spheroids and monolayer respectively (Fig. 4a and b). To confirm that this induction was seen also at the protein level, we analyzed conditioned medium by gelatin zymography. As shown in Fig. 4c, TGF- β induces pro-MMP2 and both pro- and active MMP9 in M4 cells.

To further investigate the role of MMPs in 3D invasion, spheroids of M4 were analyzed in the presence or absence of the general, broad-spectrum, MMP-inhibitor

GM6001. Interestingly, GM6001 strongly inhibited TGF- β -induced invasion (Fig. 4d, e), but had no significant effect on the basal invasion. We subsequently analyzed the effect of a selective MMP2/9 inhibitor [39]. Importantly, treatment of M4 spheroids with selective MMP2/9 inhibitor like the broad-spectrum inhibitor reduced TGF- β -induced invasion without an effect on basal invasion (Fig 4f, g).

As the TGF- β -induced invasion of M4 spheroids was dependent on Smad3/Smad4 (Fig. 3), we next examined the role of Smad3 and 4 on TGF- β -induced MMP2 and 9 expression. Both knockdown of Smad3 and Smad4 resulted in strongly reduced TGF- β -induction of MMP2 and 9 in M4 cells (Fig. 4h). Taken together, TGF- β -induced MMP2 and 9 expression is dependent on both Smad3 and Smad4, and is critical for TGF- β -induced invasion of M4 cells in this spheroid model system

Discussion

To increase our understanding of breast cancer cell invasion and the role of TGF- β therein, we established a spheroid model in which MCF10A1 cells and its malignant derivatives invade into a collagen matrix in a TGF- β -dependent manner. When comparing the invasive properties of the different MCF10A1 cell lines we found that basal invasion as well as TGF- β -induced invasion increased from the relatively benign M1 cells, to higher levels in the RAS-transformed M2 derivative, to even higher levels in the metastatic M4 variant, and thus nicely correlated with the relative state of aggressiveness of these three cell lines [24,25,33]. In contrast, there was no correlation between invasion and cell proliferation, and the growth inhibitory effect of TGF- β on the cell lines was only weak. The fact that the relatively benign M1 cells showed only a minor growth-inhibitory effect upon TGF- β treatment might be due to

chromosomal rearrangements during immortalization, leading to loss of the CDKN2A locus and amplification of MYC [40,41].

Our spheroid invasion assay resembles the *in vivo* process more closely than 2D models, because cells in collagen I-embedded spheroids are amongst others in different metabolic states and interact in more natural fashion with their surroundings [29]. Moreover, the composition of extracellular matrix in breast cancer is often altered, resulting in fibrotic stiff foci with a high collagen I content. It has been demonstrated that increased collagen I content promotes breast cancer formation and invasion [42] and is associated with greater incidence of metastasis [43]. In a previously developed 3D model by Bissell and co-workers cells are grown in a reconstituted basement membrane (rBM) matrix. This model provides a rapid assay to distinguish between normal and malignant mammary epithelium but focuses mainly on cell morphology [44]. In this assay morphogenesis and organization of the distinct MCF10A cell lines inversely correlates with malignancy [45,46]. In addition, 3D cultures of MCF10A cell lines have been used to assess sensitivity to kinase inhibitors [47]. Our spheroid model complements these assays by specifically focusing on invasion. Moreover, as it is easy to conduct and very quantifiable it can also be used for screening.

In our assays the basal 3D invasion was strongly inhibited by treatment with SB-431542, an inhibitor of type I receptors for TGF- β , Activin and Nodal. This suggests that cells produce TGF- β -like activity and stimulate invasion in an autocrine manner. This is in agreement with a recent report in which it is shown that the ECM can induce TGF- β signaling in the absence of TGF- β [48]. We cannot exclude that Activins or Nodal also contribute to basal invasion. In fact, Activin and Nodal have also been implicated in breast cancer progression [49–51]. However, Activin-A only

very weakly induced transcriptional activity and failed to induce invasion in our spheroid model.

Our results reveal a critical role for Smad3 and Smad4 in TGF- β -induced invasion of M4 cells. This is consistent with our previous findings that had demonstrated a key role for Smad3 and Smad4 in TGF- β -induced EMT and breast cancer metastasis [17,32,52]. Abrogation of the Smad pathway in M4 cells by overexpression of a Smad-binding defective mutant of T β RI or a dominant negative Smad3 mutant was also reported to suppress metastasis [53,54]. However, our results do not exclude a role for non-Smad intracellular signaling pathways downstream of TGF- β receptors I. Various studies have shown that RAS and TGF- β collaborate in promoting malignant progression of breast cancer [26,27]. Both TGF- β and RAS can activate the MAP kinases ERK, JNK and p38 and their down-stream transcription factors, such as AP-1 family members. Interestingly, in the MCF10A cell lines Smads, MAPKs as well as AP-1 proteins have been reported to contribute to TGF- β -induced migration and MMP induction [26,53]. However, it remains to be established whether and which MAPK and AP-1 members collaborate with Smad proteins to mediate basal and/or TGF- β -induced invasion of the MCF10A cell lines in our spheroid model system.

Our studies reveal a key role for MMP2 and MMP9 in TGF- β -induced invasion of the highly aggressive M4 spheroids. MMP2 and 9 were initially known for their ability to degrade native type IV collagen [55], in line with the idea that the main function of MMPs in invasion was degradation of the extracellular matrix, in particular the basal lamina [20]. Various matrix components that can be degraded by MMP2 and MMP9 are in fact produced by the epithelial cells themselves. However, besides degradation of extracellular matrix MMPs can also activate growth factors,

including TGF- β , and cleave adhesion molecules, such as E-cadherin [36]. It is likely that these functions of MMP2 and 9 also contribute to TGF- β -induced invasion.

MMP2 and 9 appear attractive targets for therapeutic intervention of breast cancer invasion. However, MMPs are multifunctional proteins and may also have anti-tumor actions. The latter appears in particular an issue for targeting of MMP9 [22]. Tumors of K14-HPV16 mice in a null MMP9 background were found to be more aggressive, indicating that MMP9 inhibits certain aspects of tumor progression [56]. On the other hand, knockdown of MMP9 reduces metastasis of T β RI-expressing cells [57]. This does not appear to be the case for MMP2, as overexpression in MDA-MB-231 cells augments orthotopic tumor growth and metastasis in nude mice [58]. In human cancer cells, MMP2 is one of the predictors for lung metastasis [38]. The development of specific MMP inhibitors remains a challenge, as the enzymatic pocket of these proteins does not differ from one another.

One striking finding is that the basal invasion of M4 spheroids is not affected by the MMP inhibitors. This is in contrast to the results obtained with the T β RI inhibitor, which blocks both basal and TGF- β -induced invasion. One could speculate that basal invasion depends on other factors induced by TGF- β , whereas MMPs are necessary for overt invasion.

In conclusion, we have established a 3D model for TGF- β -induced invasion. Using this model, we demonstrate that Smad3 and Smad4 are crucial for TGF- β -induced invasion by inducing MMP2 and MMP9. This supports the idea that targeting these molecules might aid in the prevention of metastasis in patients. The 3D assay also offers a valuable screening model system to further study TGF- β /Smad- and MMP2- and MMP9-dependent breast cancer invasion.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgements

We thank our colleagues, in particular Lukas Hawinkels, for valuable discussion and help with experiments. We are grateful to Niek Henriquez, Petra van Overveld and Geertje van der Horst for help with our experiments to set up the invasion assay. We thank Ed Leof (Mayo Clinic, Minnesota, USA) and Ken Iwata (OSI Pharmaceuticals, New York, USA), for reagents, Fred Miller (Barbara Ann Karmanos Cancer Institute, Detroit, USA) for the cell lines. This work was supported by the Dutch Cancer Society (RUL 2005-3371), European Union Framework 6 grant BRECOSM (5032240) and Tumor Host Genomics (518198), Centre for Biomedical Genetics, Swedish Cancerfonden (09 0773) and Ludwig Institute for Cancer Research.

References

1. Massagué J (2008) TGF β in Cancer. *Cell* 134:215-230. doi: 10.1016/j.cell.2008.07.001
2. Akhurst RJ, Derynck R (2001) TGF- β signaling in cancer--a double-edged sword. *Trends Cell Biol* 11:S44-S51. doi: 10.1016/S0962-8924(01)02130-4
3. Ghellal A, Li C, Hayes M, Byrne G, Bundred N, Kumar S (2000) Prognostic significance of TGF β 1 and TGF β 3 in human breast carcinoma. *Anticancer Res* 20:4413-4418
4. Sheen-Chen SM, Chen HS, Sheen CW, Eng HL, Chen WJ (2001) Serum Levels of Transforming Growth Factor β 1 in Patients With Breast Cancer. *Arch Surg* 136:937-940
5. Ivanovic V, Todorovic-Rakovic N, Demajo M, Neskovic-Konstantinovic Z, Subota V, Ivanisevic-Milovanovic O, Nikolic-Vukosavljevic D (2003) Elevated plasma levels of transforming growth factor- β 1 (TGF- β 1) in patients with advanced breast cancer: association with disease progression. *Eur J Cancer* 39:454-461. doi: 10.1016/S0959-8049(02)00502-6
6. Desruisseau S, Palmari J, Giusti C, Romain S, Martin PM, Berthois Y (2006) Determination of TGF β 1 protein level in human primary breast cancers and its relationship with survival. *Br J Cancer* 94:239-246. doi: 10.1038/sj.bjc.6602920
7. ten Dijke P, Hill CS (2004) New insights into TGF- β -Smad signalling. *Trends in Biochemical Sciences* 29:265-273. doi: 10.1016/j.tibs.2004.03.008
8. Moustakas A, Heldin CH (2009) The regulation of TGF β signal transduction. *Development* 136:3699-3714. doi: 10.1242/dev.030338
9. Chen CR, Kang Y, Massagué J (2001) Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor β growth arrest program. *Proc Natl Acad Sci U S A* 98:992-999
10. Hannon GJ, Beach D (1994) p15INK4B is a potential effector of TGF- β -induced cell cycle arrest. *Nature* 371:257-261. doi: 10.1038/371257a0
11. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF (1995) Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. *Proc Natl Acad Sci U S A* 92:5545-5549
12. Levy L, Hill CS (2006) Alterations in components of the TGF- β superfamily signaling pathways in human cancer. *Cytokine Growth Factor Rev* 17:41-58. doi: 10.1016/j.cytogfr.2005.09.009
13. Gomis RR, Alarcon C, Nadal C, Van PC, Massagué J (2006) C/EBP β at the core of the TGF β cytostatic response and its evasion in metastatic breast cancer cells. *Cancer Cell* 10:203-214. doi: 10.1016/j.ccr.2006.07.019

14. Wakefield LM, Piek E, Bottinger EP (2001) TGF-beta signaling in mammary gland development and tumorigenesis. *J Mammary Gland Biol Neoplasia* 6:67-82. doi: 10.1023/A:1009568532177
15. Dumont N, Arteaga CL (2000) Transforming growth factor- β and breast cancer: Tumor promoting effects of transforming growth factor- β . *Breast Cancer Res* 2:125-132. doi: 10.1186/bcr44
16. ten Dijke P, Goumans MJ, Itoh F, Itoh S (2002) Regulation of cell proliferation by Smad proteins. *J Cell Physiol* 191:1-16. doi: 10.1002/jcp.10066
17. Deckers M, van DM, Buijs J, Que I, Lowik C, van der Pluijm G, ten Dijke P (2006) The tumor suppressor Smad4 is required for transforming growth factor β -induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. *Cancer Res* 66:2202-2209. doi: 10.1158/0008-5472.CAN-05-3560
18. Vilorio-Petit AM, David L, Jia JY, Erdemir T, Bane AL, Pinnaduwege D, Roncari L, Narimatsu M, Bose R, Moffat J, Wong JW, Kerbel RS, O'Malley FP, Andrulis IL, Wrana JL (2009) A role for the TGF β -Par6 polarity pathway in breast cancer progression. *Proc Natl Acad Sci U S A* 106:14028-14033. doi: 10.1073/pnas.0906796106
19. Xu J, Lamouille S, Derynck R (2009) TGF- β -induced epithelial to mesenchymal transition. *Cell Res* 19:156-172. doi: 10.1038/cr.2009.5
20. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen. *Nature* 284:67-68. doi: 10.1038/284067a0
21. Weigelt B, Peterse JL, van 't Veer LJ (2005) Breast cancer metastasis: markers and models. *Nat Rev Cancer* 5:591-602. doi: 10.1038/nrc1670
22. Overall CM, Kleinfeld O (2006) Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. *Nat Rev Cancer* 6:227-239. doi: 10.1038/nrc1821
23. Soule HD, Maloney TM, Wolman SR, Peterson WD, Jr., Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC (1990) Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. *Cancer Res* 50:6075-6086
24. Strickland LB, Dawson PJ, Santner SJ, Miller FR (2000) Progression of premalignant MCF10AT generates heterogeneous malignant variants with characteristic histologic types and immunohistochemical markers. *Breast Cancer Res Treat* 64:235-240. doi: 10.1023/A:1026562720218
25. Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, Mohamed AN, Wolman SR, Heppner GH, Miller FR (2001) Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. *Breast Cancer Res Treat* 65:101-110. doi: 10.1023/A:1006461422273

26. Kim ES, Kim MS, Moon A (2004) TGF- β -induced upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK signaling in MCF10A human breast epithelial cells. *Int J Oncol* 25:1375-1382
27. Miyazono K (2009) Transforming growth factor- β signaling in epithelial-mesenchymal transition and progression of cancer. *Proc Jpn Acad Ser B Phys Biol Sci* 85:314-323. doi: 10.2183/pjab.85.314
28. Smalley KS, Lioni M, Herlyn M (2006) Life isn't flat: taking cancer biology to the next dimension. *In Vitro Cell Dev Biol Anim* 42:242-247. doi: 10.1290/0604027.1
29. Lin RZ, Chang HY (2008) Recent advances in three-dimensional multicellular spheroid culture for biomedical research. *Biotechnol J* 3:1172-1184. doi: 10.1002/biot.200700228
30. Ohmori T, Yang JL, Price JO, Arteaga CL (1998) Blockade of tumor cell transforming growth factor- β s enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. *Exp Cell Res* 245:350-359. doi: 10.1006/excr.1998.4261
31. Graham CH, Kobayashi H, Stankiewicz KS, Man S, Kapitan SJ, Kerbel RS (1994) Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents. *J Natl Cancer Inst* 86:975-982
32. Petersen M, Pardali E, van der Horst G, Cheung H, van den Hoogen C, van der Pluijm G, ten Dijke P (2010) Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis. *Oncogene* 29:1351-1361. doi: 10.1038/onc.2009.426
33. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, Wakefield LM (2003) TGF- β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. *J Clin Invest* 112:1116-1124. doi: 10.1172/JCI18899
34. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor- β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. *Mol Pharmacol* 62:65-74. doi: 10.1124/mol.62.1.65
35. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL, Massagué J (2005) Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. *Proc Natl Acad Sci U S A* 102:13909-13914. doi: 10.1073/pnas.0506517102
36. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. *Nat Rev Cancer* 2:161-174. doi: 10.1038/nrc745
37. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM,

- Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. *Nature* 415:530-536. doi: 10.1038/415530a
38. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massagué J (2005) Genes that mediate breast cancer metastasis to lung. *Nature* 436:518-524. doi: 10.1038/nature03799
39. Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M (1998) Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. *J Med Chem* 41:640-649. doi: 10.1021/jm9707582
40. Cowell JK, Laduca J, Rossi MR, Burkhardt T, Nowak NJ, Matsui S (2005) Molecular characterization of the t(3;9) associated with immortalization in the MCF10A cell line. *Cancer Genet Cytogenet* 163:23-29. doi: 10.1016/j.cancergencyto.2005.04.019
41. Kadota M, Yang HH, Gomez B, Sato M, Clifford RJ, Meerzaman D, Dunn BK, Wakefield LM, Lee MP (2010) Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. *PLoS One* 5:e9201. doi: 10.1371/journal.pone.0009201
42. Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, White JG, Keely PJ (2008) Collagen density promotes mammary tumor initiation and progression. *BMC Med* 6:11. doi: 10.1186/1741-7015-6-11
43. Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular signature of metastasis in primary solid tumors. *Nat Genet* 33:49-54. doi: 10.1038/ng1060
44. Petersen OW, Ronnov-Jessen L, Howlett AR, Bissell MJ (1992) Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. *Proc Natl Acad Sci U S A* 89:9064-9068
45. Debnath J, Muthuswamy SK, Brugge JS (2003) Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. *Methods* 30:256-268. doi: 10.1016/S1046-2023(03)00032-X
46. Li Q, Mullins SR, Sloane BF, Mattingly RR (2008) p21-Activated kinase 1 coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional culture model for premalignant progression of human breast cancer. *Neoplasia* 10:314-329. doi: 10.1593/neo.07970
47. Li Q, Chow AB, Mattingly RR (2010) Three-dimensional overlay culture models of human breast cancer reveal a critical sensitivity to mitogen-activated protein kinase kinase inhibitors. *J Pharmacol Exp Ther* 332:821-828. doi: 10.1124/jpet.109.160390

48. Garamszegi N, Garamszegi SP, Samavarchi-Tehrani P, Walford E, Schneiderbauer MM, Wrana JL, Scully SP (2010) Extracellular matrix-induced transforming growth factor-beta receptor signaling dynamics. *Oncogene* 29:2368-2380. doi: 10.1038/onc.2009.514
49. Incorvaia L, Badalamenti G, Rini G, Arcara C, Fricano S, Sferrazza C, Di TD, Gebbia N, Leto G (2007) MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. *Anticancer Res* 27:1519-1525
50. Strizzi L, Postovit LM, Margaryan NV, Seftor EA, Abbott DE, Seftor RE, Salomon DS, Hendrix MJ (2008) Emerging roles of nodal and Cripto-1: from embryogenesis to breast cancer progression. *Breast Dis* 29:91-103
51. Adkins HB, Bianco C, Schiffer SG, Rayhorn P, Zafari M, Cheung AE, Orozco O, Olson D, De LA, Chen LL, Miatkowski K, Benjamin C, Normanno N, Williams KP, Jarpe M, LePage D, Salomon D, Sanicola M (2003) Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. *J Clin Invest* 112:575-587. doi: 10.1172/JCI17788
52. Dzwonek J, Preobrazhenska O, Cazzola S, Conidi A, Schellens A, van DM, Stubbs A, Klippel A, Huylebroeck D, ten Dijke P, Verschueren K (2009) Smad3 is a key nonredundant mediator of transforming growth factor β signaling in Nme mouse mammary epithelial cells. *Mol Cancer Res* 7:1342-1353. doi: 10.1158/1541-7786.MCR-08-0558
53. Tian F, Byfield SD, Parks WT, Stuelten CH, Nemani D, Zhang YE, Roberts AB (2004) Smad-binding defective mutant of transforming growth factor β type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. *Cancer Res* 64:4523-4530. doi: 10.1158/0008-5472.CAN-04-0030
54. Tian F, DaCosta BS, Parks WT, Yoo S, Felici A, Tang B, Piek E, Wakefield LM, Roberts AB (2003) Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. *Cancer Res* 63:8284-8292
55. Stetler-Stevenson WG (1994) Progelatinase A activation during tumor cell invasion. *Invasion Metastasis* 14:259-268
56. Coussens LM, Tinkle CL, Hanahan D, Werb Z (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. *Cell* 103:481-490. doi: 10.1016/S0092-8674(00)00139-2
57. Safina A, Vandette E, Bakin AV (2007) ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells. *Oncogene* 26:2407-2422. doi: 10.1038/sj.onc.1210046
58. Tester AM, Waltham M, Oh SJ, Bae SN, Bills MM, Walker EC, Kern FG, Stetler-Stevenson WG, Lippman ME, Thompson EW (2004) Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and

experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice. *Cancer Res* 64:652-658

Figure legends

Figure 1 TGF- β -induced invasion of spheroids of normal MCF10A1 (M1), RAS-transformed MCF10AneoT (M2) and its metastatic derivative MCF10CA1a (M4). M1, M2 and M4 spheroids embedded into collagen were treated with 5ng/ml of TGF- β for 48 hr as indicated (**a,b**). **a** Representative pictures taken at the day of embedding and two days later. **b** Relative invasion was quantified as area difference on day 2 minus day 0. The results are expressed as mean \pm s.d. (M1: n=7, M2 and M4: n=4). **c** Proliferation of M1, M2 and M4 cells in the presence and absence of TGF- β . Cell viability was measured 0, 24, 48 and 72 hr after 5ng/ml TGF- β treatment using the MTS assay. Relative growth was determined by calculating the absorbance at 490 nm for each time point relative to 0 hr measurement. The results are expressed as mean \pm SEM. of three independent experiments performed in triplicate. Significance: ***P<0.001.


Figure 2 Basal and TGF- β -induced spheroid invasion is inhibited by SB-431542. M1, M2 and M4 spheroids were embedded into collagen and treated with 5ng/ml TGF- β and/or 10 μ M SB-431542 as indicated. **a** Representative pictures taken after 2 days. **b** Relative invasion was quantified as area difference on day 2 minus day 0. The results are expressed as mean \pm s.d. (M1: n=3, M2 and M4: n=4). Significance: ***P<0.001, **P<0.01, *P<0.05.


Figure 3 TGF- β -induced spheroid invasion is Smad3/4 dependent. MCF10CA1a (M4) cells were transduced with lentiviruses expressing shRNA against Smad4 or miRNA against Smad3 and the appropriate control viruses. **a** Cells were stimulated



with 5ng/ml of TGF- β for 16h. Protein lysates were separated by SDS-PAGE and subjected to western blot analysis using Smad3-, Smad4-, phospho-Smad2- and phospho-Smad3-specific antibodies. **b** Cells were transfected with CAGA₁₂-luc transcriptional reporter and subsequently stimulated with 5ng/ml of TGF- β for 16h. Relative luciferase activity (CPU) is expressed as mean \pm s.d. of triplicate cultures. **c,d** Spheroids were embedded into collagen and treated with 5ng/ml of TGF- β for 2 days. **c** Representative pictures taken after 2 days. **d** Relative invasion was quantified as area difference on day 2 minus day 0. Results are expressed as mean \pm s.d. (sh-Smad4: n=4, miR-Smad3: n=3). Significance: ***P<0.001, *P<0.05.

Figure 4 TGF- β -induced spheroid invasion is dependent on matrix metalloproteinase activity. **a,b** RNA was isolated from spheroids (**a**) or monolayer (**b**) of M4 cells stimulated for 24 hr with or without TGF- β (5ng/ml). Q-PCR for MMP2 and MMP9 was performed using ARP as internal control. **c** Conditioned medium was harvested from M4 cells stimulated with or without TGF- β (5 ng/ml) for 48 hr and subjected to gelatin zymography **d-g** Inhibition of matrix metalloproteinases (MMPs) hampers TGF- β -induced invasion in MCF10CA1a (M4). M4 spheroids were embedded into collagen and incubated with 5ng/ml TGF- β , and/or general MMP inhibitor GM6001 (1 μ M) (**d,e**) or selective MMP 2/9 inhibitor (1 μ M) (**f,g**) as indicated. **d,f** Representative pictures taken after 2 days. **e,g** Invasion was quantified as area difference on day 2 minus day 0. Results are expressed as mean \pm s.d (**e**: DMSO: n=7; GM6001: n=8; **g**: DMSO: n=9,12; inhibitor: n=23,24). **h** RNA was isolated from M4 cells transduced with Smad knock-down or non-targeting control viruses and stimulated for 24 hr with 5ng/ml TGF- β . Q-PCR for MMP2 and MMP9 was

performed using ARP as internal control. One representative experiment out of three independent experiments is shown. Significance * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.







B Fig 3







Fig 4

